Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Benign recurrent intrahepatic cholestasis 1 (BRIC1) is characterized by episodes of liver dysfunction called cholestasis, during which the liver cells have a reduced ability to release a digestive fluid called bile. These episodes can last from weeks to months, and the time between them, during which there are usually no symptoms, can vary from weeks to years.Most people with BRIC1have their first episode of cholestasisintheir teens or twenties. Symptoms oftenpresent with severe itchiness, followed by yellowing of the skin and whites of the eyes (jaundice) a few weeks later. BRIC1 is caused by mutations in the ATP8B1 gene. This condition is inherited in an autosomal recessive pattern.BRIC1generally does not cause lasting damage to the liver. However, in rare cases, episodes of liver dysfunction may develop into a more severe, permanent form of liver disease known as progressive familial intrahepatic cholestasis (PFIC). BRIC and PFIC are sometimes considered to be part of a spectrum of intrahepatic cholestasis disorders of varying severity.
Features include: Conjugated hyperbilirubinemia, Hearing loss (hearing impairment), Intermittent jaundice, and Enlarged liver (hepatomegaly) and 4 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 4 | Intermittent jaundice, Enlarged liver (hepatomegaly), Intrahepatic cholestasis with episodic jaundice |
Lab test results | 2 | Conjugated hyperbilirubinemia, Increased serum bile acid concentration |
Ears | 1 | Hearing loss (hearing impairment) |
Skin | 1 | Pruritus |
ATP8B1 deficiency encompasses a phenotypic spectrum ranging from severe through moderate to mild. Severe ATP8B1 deficiency is characterized by infantile-onset cholestasis that progresses to cirrhosis, hepatic failure, and death. Mild-to-moderate ATP8B1 deficiency was initially thought to involve intermittent symptomatic cholestasis with a lack of hepatic fibrosis; however, some persons with clinically diagnosed mild disease have hepatic fibrosis on biopsy. Furthermore, in some persons with ATP8B1 deficiency the clinical findings can span the phenotypic spectrum, shifting over time from the mild end (episodic cholestasis) to the severe end of the spectrum (persistent cholestasis) . Family members with the same ATP8B1 pathogenic variants do not always have disease of the same clinical severity. In addition, clinical severity can change over time: mild disease diagnosed in childhood may progress in adulthood to severe disease . Severe ATP8B1 deficiency. The age and onset of manifestations of severe ATP8B1 deficiency vary among affected individuals. Affected children typically present in the first year of life, often with severe pruritus and jaundice . The onset of pruritus is often difficult to pinpoint because detection depends on an infant's ability to scratch in a coordinated manner; thus, in some infants irritability may be an initial manifestation of pruritus. Some individuals have been treated for long periods for chronic dermatologic conditions because of longstanding pruritus without typical findings of liver disease. Secondary manifestations such as coagulopathy (due to vitamin K deficiency), malabsorption, and poor weight gain may present earlier than age three months. While onset in the first year of life with progression to cirrhosis by the end of the first decade of life is typical in severe ATP8B1 deficiency, both interfamilial and intrafamilial variability have been noted among affected individuals with the same pathogenic variants [, , , , , ]. Mild-to-moderate ATP8B1 deficiency is characterized by intermittent episodes of cholestasis, severe pruritus, and jaundice in the absence of extrahepatic bile duct obstruction. Episodes may last from weeks to months. Symptom-free intervals may last from months to years. Individuals may have variable or unknown triggers for some or all bouts of cholestasis. In truly mild disease, chronic liver damage does not develop; however, in some individuals in whom ATP8B1 deficiency initially appears mild, clinical monitoring over time or detection of fibrosis on liver biopsy may indicate disease of moderate severity . More recently, ATP8B1 pathogenic variants have been reported in some adults with cryptogenic cirrhosis, suggesting further broadening of the phenotypic spectrum of ATP8B1 deficiency to include development of liver disease beyond the first decades of life . See for an overview of the distinguishing features of the severe and mild-to-moderate phenotypes. Table 3. ATP8B1 Deficiency: Comparison of Phenotypes by Select Features
ATP8B1 encodes ATPase phospholipid transporting 8B1 (1,251 aa). Catalytic component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of phospholipids, in particular phosphatidylcholines (PC), from the outer to the inner leaflet of the plasma membrane.
Benign recurrent intrahepatic cholestasis type 1 is associated with mutations in the ATP8B1 gene on chromosome 18.
ATP8B1 is classified as a druggable target (Enzyme and Transporter categories) with score 8.7.
Disease severity generally correlates with variant type:
Source: GeneReviews — "ATP8B1 Deficiency"
No consensus clinical diagnostic criteria for ATP8B1 deficiency have been published.
ATP8B1 deficiency should be suspected in individuals with the following findings, findings, histologic findings on , and . While mild-to-moderate and severe phenotype classifications have been proposed, ATP8B1 deficiency occurs along a continuous spectrum of severity.
Severe ATP8B1 deficiency. Unremitting cholestasis (typically beginning within the first few months of life) manifesting as :
Jaundice
Clinically significant diarrhea
Failure to thrive
Hemorrhage (due to the coagulopathy of vitamin K deficiency)
Hepatosplenomegaly
Pruritus
Discolored and/or pale stools
Source: GeneReviews — "ATP8B1 Deficiency"
summarizes other inherited disorders with cholestatic liver disease typically characterized by low or normal serum gamma-glutamyltranspeptidase (-GT) levels that need to be distinguished from the much more common cholestatic disorders characterized by elevated serum -GT level (including childhood-onset progressive familial intrahepatic cholestasis caused by biallelic ABCB4 pathogenic variants [PFIC3; OMIM 602347]). Table 4. Autosomal Recessive Pediatric Cholestatic Liver Disorders with Low or Normal Serum -GT Levels in the Differential Diagnosis of ATP8B1 Deficiency
Gene | Disorder | Typical Clinical Characteristics at Diagnosis | Characteristic Histology at Diagnosis | Other Serum Studies at Diagnosis |
|---|---|---|---|---|
ATP8B1 | ATP8B1 deficiency (topic of this GeneReview; incl for reference) |
Genetic testing for ATP8B1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for benign recurrent intrahepatic cholestasis type 1 has been reported in the published literature.
No approved treatments are currently available for benign recurrent intrahepatic cholestasis type 1. The disease remains an area of unmet medical need.
Clinical practice guidelines for ATP8B1 deficiency have not been published. Evaluations at Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with ATP8B1 deficiency, all possible manifestations of this disorder (if not addressed as part of the evaluation that led to the diagnosis) should be included in the initial evaluation. See . Table 5. Recommended Evaluations Following Initial Diagnosis in Individuals with ATP8B1 Deficiency
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Comprehensive medical history physical exam | — |
Cholestasis | Assessment by hepatologist | Standard biochemical assays of hepatocellular function hepatobiliary injury; Liver imaging; Liver biopsy if indicated by imaging studies /or biochemical assays; Assess for portal hypertension. Chronic liver disease |
loss | By audiologist | In all persons whether symptomatic or not Resistance to |
parathyroid hormone | By endocrinologist | When serum levels of calcium are low phosphorus levels are Pancreatitis or pancreatic |
exocrineinsufficiency | By hepatologist |
Source: GeneReviews — "ATP8B1 Deficiency"
Susceptibility to sensorineural hearing loss in ATP8B1 deficiency may argue against use of aminoglycoside antibiotics or other potentially ototoxic agents. Oral contraceptive therapy can induce and/or exacerbate episodes of cholestasis.
Source: GeneReviews — "ATP8B1 Deficiency"
Cystic fibrosis transmembrane conductance regulator corrector compounds improved trafficking of mutated ATP8B1 protein in cell culture studies , providing support for the concept that these compounds may be suitable to be included in future therapeutic regimens for ATP8B1 deficiency. Ileal bile acid transporter inhibitors have shown reduction in bile acid levels and reduced pruritus in children; various clinical trials are underway . Recent FDA approval should prompt future real-world experience reports that are needed to better appreciate the true effectiveness of this therapy. Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "ATP8B1 Deficiency"
View trials for benign recurrent intrahepatic cholestasis type 1
Table 7. Recommended Surveillance for Individuals with ATP8B1 Deficiency
System/Concern | Evaluation | Frequency |
|---|---|---|
Constitutional | Comprehensive medical history physical exam | At least annually; frequency may depend on severity of disease. Cholestasis |
w/known HL | Per treating audiologist | For those w/o |
known HL | Screening audiogram | Every 5 yrs SNHL = sensorineural hearing loss 1. Note: Monitoring for hepatobiliary malignancy has not been shown to be necessary in ATP8B1 deficiency. |
Source: GeneReviews — "ATP8B1 Deficiency"
No clinical trials have been registered for benign recurrent intrahepatic cholestasis type 1.
8 publications have been identified in PubMed for benign recurrent intrahepatic cholestasis type 1. Research spans Case Report / Case Series (63%), Diagnostic / Biomarker (13%), and Review / Meta-Analysis (13%).
Prince A (2025). [PMID: 41084973](https://pubmed.ncbi.nlm.nih.gov/41084973/). *Cell cycle (Georgetown, Tex.)*. [Basic Science / Preclinical]
Vo VH (2025). [PMID: 40880677](https://pubmed.ncbi.nlm.nih.gov/40880677/). *Case reports in gastroenterology*. [Case Report / Case Series]
Memon R (2025). [PMID: 40530431](https://pubmed.ncbi.nlm.nih.gov/40530431/). *Advances in anatomic pathology*. [Case Report / Case Series]
Demir E (2025). [PMID: 40771188](https://pubmed.ncbi.nlm.nih.gov/40771188/). *Molecular syndromology*. [Case Report / Case Series]
Di Giorgio A (2025). [PMID: 40622192](https://pubmed.ncbi.nlm.nih.gov/40622192/). *Liver international : official journal of the International Association for the Study of the Liver*. [Diagnostic / Biomarker]
Shao J (2025). [PMID: 40261314](https://pubmed.ncbi.nlm.nih.gov/40261314/). *Science progress*. [Case Report / Case Series]
Liu F (2024). [PMID: 38607191](https://pubmed.ncbi.nlm.nih.gov/38607191/). *Alternative therapies in health and medicine*. [Case Report / Case Series]
Xu YX (2024). [PMID: 39015910](https://pubmed.ncbi.nlm.nih.gov/39015910/). *World journal of clinical cases*. [Review / Meta-Analysis]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 6:46 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Feature | Severe | Mild to Moderate |
|---|---|---|
Hepatic | Cholestasis | Near universal |
Pruritus | Near universal | Common/intermittent |
Nutritional deficiencies(incl vitamins A, D, E, K) | Common | Rare |
Poor growth | Common | Rare |
Diarrhea | Common | Rare |
Chronic liver disease | Common | Some |
Extrahepatic | Sensorineural hearing loss | Common |
Pancreatitis or pancreaticexocrine insufficiency | Some | Some Cholestasis. Although children with the severe phenotype may initially experience episodes of severe cholestasis followed by disease-free intervals, cholestasis eventually becomes constant. |
Source: GeneReviews — "ATP8B1 Deficiency"
Multisystem disease |
Bland canalicular cholestasis; Coarsely granular canalicular bile |
Cholesterol concentrations usually not; Often marked of total bile acids1,2; Modest of transaminases |
ABCB11 | ABCB11 deficiency (severe PFIC2; OMIM 601847) | Primary manifestations are limited to the liver.3; Hepatobiliary malignancy (HCC cholangiocarcinoma) in childhood4,5; High incidence of gallstones | Giant cell transformation necrosis of hepatocytes; Bile pigment accumulation in hepatocytes in lumina of bile canaliculi; Ultrastructural study of canalicular bile does not identify coarse granularity.6; Expression of ectoenzymes (e.g. | Transaminase activity values are higher in ABCB11 deficiency (than in ATP8B1 deficiency).1,2; Albumin, bile acid, AFP concentrations tend to be higher in severe ABCB11 deficiency.1,2 |
MYO5B | MYO5B deficiency | Variable degree of intestinal involvement | Giant cell change; Hepatocellular canalicular cholestasis; Poor expression of -GT along bile canaliculi8 | — |
NR1H4 | PFIC5 (OMIM 617049) | Early-onset coagulopathy | Intralobular cholestasis; Ductular reaction; Giant cell transformation | Markedly AFP |
TJP2 | PFIC4 (OMIM 615878) | Some extrahepatic features | Bland cholestasis | — |
USP539 | USP53 | Some extrahepatic features incl deafness | Intralobular cholestasis; Giant cell transformation; Fibrotic changes; Ductular reaction; Ultrastructural changes may incl elongated hepatocyte-hepatocyte tight junctions | AFP = alphafetoprotein; HCC = hepatocellular carcinoma; PFIC = progressive familial intrahepatic cholestasis; -GT = gamma-glutamyltranspeptidase 1. 2. 3. Extrahepatic disease manifestations are less common in ABCB11 deficiency than in ATP8B1 deficiency. |
Source: GeneReviews — "ATP8B1 Deficiency"
Genetic counseling | By genetics professionals2 | To inform patients families re nature, MOI, implications of ATP8B1 deficiency to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with ATP8B1 Deficiency Manifestation/Concern | Treatment | Considerations/Other Cholestasis |
Severe ATP8B1 deficiency | Pharmacotherapy | Ineffective Surgical interruption of enterohepatic circulation1,2 |
Mild-to-moderate ATP8B1 deficiency | Nasobiliary drainage4 extracorporeal liver support5 | May hasten end of episode of cholestasis Surgical interruption of enterohepatic circulation |
Severe ATP8B1 deficiency | Choleretic agents (e.g., phenobarbital UDCA, cholestyramine, rifampin, antihistamines, carbamazepine, sertraline, naltrexone, UVB light therapy, plasmapheresis) | Relatively ineffective do not alter progression to end-stage liver disease.; Future efforts focusing on real-world experience w/recently FDA-approved IBAT inhibitors are needed.6 |
Mild-to-moderate ATP8B1 deficiency | Rifampicin, UDCA, sertraline,7 naltrexone,8 bile acid binding resin | May be efficacious9 |
Secretory diarrhea | May require IV fluids | Bile acid chelators10 may ameliorate diarrhea after LTX, as they may divert bile produced by allograft away from the native gut.11; Clonidine has palliated diarrhea after LTX in some persons.12; Consider diversion at time of transplantation to mitigate post-transplant diarrhea steatohepatitis.3 |
Poor growth | Medium-chain triglyceride-based formulas | May prevent /or treat growth failure; Nasogastric tube feeding has been helpful in some.; May not be responsive to LTX |
Nutritional deficiencies (incl vitamins A, D, E, K) | Fat-soluble vitamin supplementation to alleviate malabsorption of fat-soluble vitamins | Preparations of vitamin E (e.g., tocopheryl polyethylene glycol-1000 succinate) are useful in severe cholestasis.; Vitamin K administration in newborn period (1st 28 days of life) is essential. |
Sensorineural hearing loss | Habituation per treating audiologist | Pancreatitis or pancreatic exocrine insufficiency |